<unk>  is a Platelet aggregation inhibitor that is FDA approved for the {{{indicationType}}} of prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours.   Common adverse reactions include Chest pain , Hypotension ,Injection site pain ,Abdominal pain , Nausea, Vomiting  Bleeding 
Backache.
Abiciximab
Volociximab
Dinutuximab
Brentuximab vedotin
Bavituximab
Acalabrutinib
Neratinib
Panitumumab